Benzinga · Oct 2, 2026
Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve
Edwards Lifesciences earned FDA approval for its AUTUS pediatric heart valve, designed to expand as young patients grow.
NYSE · EW
Edwards Lifesciences Corporation
Healthcare · Medical - Devices
$85.21
Up+$0.97 (+1.15%)
Updated Oct 10, 2026, 6:46 PM
SID Score
5.5/10
Composite research score
Smart Money
54/100
Neutral
- Market cap
- 49.46B
- P/E ratio
- 36.1
- Dividend yield
- 0.00%
- 52-week range
- $74.66 – $96.29
- Volume
- 3.89M
- Avg. volume
- 4.51M
Price performance · EW
EW price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
EW closed at $85.21 after 21 trading sessions, up 1.00% for the selected period.
- Last close
- $85.21
- Period change
- +1.00%
- Period low
- $84.24
- Period high
- $89.28
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $84.60 | $85.34 | $83.22 | $85.21 | 3.89M |
| Oct 8, 2026 | $85.65 | $85.78 | $82.425 | $84.24 | 6.52M |
| Oct 7, 2026 | $86.65 | $87.30 | $85.49 | $85.78 | 3.51M |
| Oct 6, 2026 | $87.54 | $87.875 | $85.94 | $86.48 | 3.38M |
| Oct 5, 2026 | $85.635 | $87.57 | $85.34 | $87.23 | 3.32M |
| Oct 2, 2026 | $85.52 | $86.48 | $84.66 | $85.15 | 2.41M |
| Oct 1, 2026 | $85.99 | $86.8388 | $84.485 | $85.19 | 3.08M |
| Sep 30, 2026 | $87.16 | $87.49 | $85.72 | $86.32 | 4.89M |
| Sep 29, 2026 | $85.70 | $88.19 | $85.70 | $88.08 | 3.38M |
| Sep 28, 2026 | $86.00 | $87.33 | $85.56 | $86.83 | 3.23M |
| Sep 25, 2026 | $86.66 | $87.11 | $84.925 | $86.29 | 3.6M |
| Sep 24, 2026 | $86.54 | $87.12 | $85.63 | $85.73 | 3.87M |
| Sep 23, 2026 | $88.70 | $88.79 | $86.06 | $86.82 | 3.62M |
| Sep 22, 2026 | $89.00 | $89.66 | $88.495 | $88.78 | 3.53M |
| Sep 21, 2026 | $88.34 | $88.59 | $87.77 | $88.34 | 3.35M |
| Sep 18, 2026 | $88.03 | $88.77 | $87.47 | $88.26 | 4.26M |
| Sep 17, 2026 | $89.21 | $89.5788 | $88.00 | $88.25 | 3.88M |
| Sep 16, 2026 | $84.99 | $89.70 | $84.84 | $89.28 | 5.01M |
| Sep 15, 2026 | $85.03 | $86.025 | $84.47 | $85.74 | 3.78M |
| Sep 14, 2026 | $85.45 | $86.26 | $85.12 | $85.52 | 2.99M |
| Sep 11, 2026 | $87.51 | $87.755 | $83.81 | $84.37 | 3.8M |
Latest EW news
The latest Smart Investors Daily articles mentioning EW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EW research
Overview
Company profile and research snapshot.
Company profile
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $95.40
- Implied upside
- —
- Analysts
- 19
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Overweight | — |
| Sep 11, 2026 | BTIG | Buy | — |
| Jul 24, 2026 | Leerink Partners | Outperform | — |
| Jul 24, 2026 | Piper Sandler | Overweight | — |
| Jul 24, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 1, 2026
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.
Benzinga · Oct 1, 2026
Edwards Lifesciences Says FDA Approves AUTUS Size-Adjustable Valve, Surgical Pulmonary Valve Designed For Pediatric Patients With Congenital Heart Disease
Edwards Lifesciences (NYSE:EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with
Yahoo · Sep 18, 2026
How Investors May Respond To Edwards Lifesciences (EW) Expanded TAVR Access And Transcatheter Valve Ambitions
Edwards Lifesciences recently outlined its structural heart growth plan, emphasizing transcatheter valve platforms such as TAVR and TMTT, alongside the impact of updated Medicare coverage that could enable 100–200 additional U.S. centers to perform TAVR procedures. A particularly important takeaway is Edwards’ ambition to build a multibillion-dollar transcatheter mitral and tricuspid business by 2030, anchored by PASCAL, EVOQUE, and Sapien M3 technologies that aim to address complex...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
